Withdrawal from Lorazepam in Critically III Children
| Autor: | Diana G. Wilkins, Denise M. Coleman, Mark R. Crowley, Robert Katz, Karen D. Dominguez, H. William Kelly |
|---|---|
| Rok vydání: | 2006 |
| Předmět: |
Male
Endpoint Determination medicine.drug_class Critical Illness medicine.medical_treatment 030204 cardiovascular system & hematology Intensive Care Units Pediatric Lorazepam Gas Chromatography-Mass Spectrometry Hypnotic 03 medical and health sciences 0302 clinical medicine Predictive Value of Tests Risk Factors Intensive care mental disorders medicine Humans Hypnotics and Sedatives Pharmacology (medical) Prospective Studies 030212 general & internal medicine Infusions Intravenous Prospective cohort study Mechanical ventilation Pediatric intensive care unit Dose-Response Relationship Drug business.industry Infant Substance Withdrawal Syndrome Clinical trial Logistic Models Child Preschool Anesthesia Sedative Female business medicine.drug |
| Zdroj: | Annals of Pharmacotherapy. 40:1035-1039 |
| ISSN: | 1542-6270 1060-0280 |
| DOI: | 10.1345/aph.1g701 |
| Popis: | Background: Sedatives are used in critically ill children to facilitate mechanical ventilation. Although tolerance and withdrawal are associated with use of sedatives, information about withdrawal from benzodiazepines in children is limited. Objective: To document the occurrence of lorazepam withdrawal in critically ill children and identify predictors for the development of withdrawal. Methods: This prospective, investigational, open-label study enrolled pediatric patients receiving a continuous infusion of lorazepam for at least 72 hours. The lorazepam dosage was tapered in a uniform fashion over 6 days by decreasing the total daily dose by 50% every other day on 3 occasions; it was then discontinued. The occurrence of withdrawal from lorazepam was determined by pediatric intensive care unit attending physicians based on clinical judgment. Patients were assessed for withdrawal twice daily beginning 48 hours after the initiation of the lorazepam taper. Assessments were continued for 72 hours after lorazepam discontinuation or until the patient experienced withdrawal, whichever came first. Patient demographic, sedative dosing, and lorazepam serum concentration data were collected to identify risk factors for withdrawal. Results: Twenty-nine patients completed the study. They received lorazepam for a median duration of about 21 days, and withdrawal occurred in 7 patients. There were no significant differences in demographic variables, lorazepam dosage or other sedative therapy, or lorazepam serum concentrations between patients with withdrawal and those without withdrawal. No predictors of withdrawal were identified. Conclusions: Withdrawal occurred in 24% of critically ill children receiving long-term sedation from lorazepam. Risk factors for withdrawal are unknown. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|